Skip to content
Head to head

Inhibrx Biosciences vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: INBX · VRTX

Updated 5 minutes ago

1-year performance, rebased to 100

INBX -10.8%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
INBXVRTX
Snapshot
Sector--Biotechnology
Last price68.97515.02
Change today-7.21%-1.08%
1-year return-13.6%+22.0%
Market cap$1.02B$130.58B
52-week range57.30 – 155.29412.27 – 568.67
Valuation
P/E (TTM)-7.6133.14
P/E percentile, own 5-yr range23rd99th
P/B-11.866.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-9.0415.32
Net profit (TTM)$-133.51M$3.88B
Revenue (TTM)$2.00M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin-6286.7%33.1%
Net margin-7082.9%30.7%
Free cash flow (TTM)$-132.70M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership104.0%96.8%
Insider activity (12mo)0 buy / 27 sell28 buy / 22 sell
Short interest (% of float)23.0%1.9%
Analyst consensus100% buy (3)95% buy / 5% hold (21)
Analyst price target$267 (+287%)$624 (+21%)
StockVane view
StockVane Quant RatingD (23)C (68)
Company
Employees1106,400
Founded20241989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.